Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
Open Access
- 1 April 2015
- journal article
- review article
- Published by Georg Thieme Verlag KG in South Asian Journal of Cancer
- Vol. 4 (2), 095-097
- https://doi.org/10.4103/2278-330x.155699
Abstract
Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in "castration syndrome", a constellation of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, osteoporosis, and fractures. Recent evidence suggests that estrogen, in the parenteral form, may emerge as an alternative to LHRHa as it offers potential benefits of arresting PC growth as well as avoiding some of the estrogen deficiency related toxicities of LHRHa by maintaining endogenous levels of estrogen.Keywords
This publication has 19 references indexed in Scilit:
- Androgen deprivation therapy complicationsEndocrine-Related Cancer, 2014
- Prostate cancer in Asian menNature Reviews Urology, 2014
- Androgen deprivation treatment in prostate cancerBMJ, 2013
- Quality of life issues in men undergoing androgen deprivation therapy: a reviewAsian Journal of Andrology, 2012
- Use of androgen deprivation therapy in prostate cancer: indications and prevalenceAsian Journal of Andrology, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5Scandinavian Journal of Urology and Nephrology, 2008
- Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancerAnnals of Oncology, 2000
- Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.1986
- The veterans administration cooperative urological research group's studies of cancer of the prostateCancer, 1973